Renal Impairment in Type 2 Diabetic Subjects

Phase 1 Completed 40 enrolled AstraZeneca Bristol-Myers Squibb · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function

Timeline

Start: 2006-03
Primary completion: 2008-10
Completion: 2008-10

Publications

Results Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	20 mg	Oral
Subject	Dapagliflozin	Small molecule	50 mg	Oral

Renal Impairment in Type 2 Diabetic Subjects

Summary

Timeline

Publications

Drugs

Indications